Skip to content

Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Paternal Age

Evaluation of the Effectiveness of Live Motile Sperm Sorting Device on In Vitro Fertilization Outcomes in Advanced Paternal Age Group

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07605182
Acronym
IVF
Enrollment
378
Registered
2026-05-22
Start date
2026-07-15
Completion date
2027-12-30
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Paternal Age, Assisted Reproductive Technology, Male Infertility

Keywords

DNA fragmentation, Advanced paternal age, ICSI, LensHooke CA0

Brief summary

Male infertility contributes significantly to infertility, particularly in advanced paternal age men where sperm DNA fragmentation is increased. Conventional density gradient centrifugation may induce oxidative stress and sperm damage. LensHooke® CA0 is a centrifugation-free sperm sorting device designed to improve sperm quality and reduce DNA fragmentation. This prospective comparative study evaluates the effectiveness of CA0 versus conventional density gradient centrifugation on post-processing sperm quality, DNA fragmentation index, blastocyst formation, euploid embryo rate, and clinical pregnancy outcomes in IVF/ICSI cycles involving men aged 40 years or older

Detailed description

Male infertility contributes to approximately 50% of all infertility cases. One of the essential steps in assisted reproductive technology (ART) is sperm preparation, which aims to select motile, morphologically normal spermatozoa with minimal DNA damage. However, conventional sperm preparation techniques involving centrifugation may increase oxidative stress and sperm DNA fragmentation. The live motile sperm sorting device LensHooke® CA0 has been proposed as an alternative to traditional density gradient centrifugation (DGC), aiming to reduce sperm damage and potentially improve IVF outcomes. LensHooke® CA0 offers several advantages: it avoids centrifugation and the mechanical stress associated with it; optimally reduces the DNA fragmentation index (DFI); minimizes the risk of premature acrosome reaction (AR); is suitable for both normozoospermic and non-normozoospermic semen samples; simplifies workflow (only three pipetting steps required: loading, medium addition, and recovery); and ensures a high degree of standardization, reducing inter-technician variability. Moreover, paternal age is an important factor influencing sperm quality and fertility potential. Studies have demonstrated that men over 40 years of age exhibit higher sperm DNA fragmentation rates, increased morphological and motility abnormalities, and are associated with a higher incidence of embryonic chromosomal abnormalities and reduced live birth rates. Therefore, this population particularly requires optimized sperm selection methods to improve IVF/ICSI outcomes. This study aims to evaluate the clinical value of this device through two primary objectives: 1. To compare sperm quality post-processing and the DNA fragmentation index between the CA0 method and the conventional DGC method in advanced paternal age group. 2. To compare the rates of blastocyst formation, euploid embryos, and clinical pregnancy between the two sperm preparation techniques in advanced paternal age group.

Interventions

DEVICELensHooke® CA0 sperm sorting device

Sperm will be processed using the CA0 device by loading 1.0 mL of semen into the lower chamber and adding 0.9 mL of pre-equilibrated sperm washing medium into the upper chamber. The device is incubated at 37 °C for a minimum of 30 minutes, followed by aspirating 0.5 mL of recovered sperm suspension for ICSI.

Sperm will be prepared by layering 1 mL of 45% medium and 1 mL of 90% medium with 1 mL of semen sample. This is followed by a first centrifugation at 1500 rpm for 15 minutes, a wash step using 2 mL G-IVF plus medium, and a second centrifugation at 1200 rpm for 10 minutes to retain 0.5 mL of the sperm suspension.

Sponsors

Vietnam Military Medical University
Lead SponsorOTHER
National Hospital of Obstetrics and Gynecology
CollaboratorOTHER
Tam Anh TP. Ho Chi Minh General Hospital
CollaboratorOTHER
Viet-Belgium Andrology and Infertility Hospital
CollaboratorUNKNOWN
Phuong Chau International Hospital
CollaboratorUNKNOWN
Dong Do Hospital
CollaboratorUNKNOWN
Vinmec Healthcare System
CollaboratorOTHER
Andrology and Fertility Hospital of Hanoi
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male partners aged ≥ 40 years * Semen analysis: volume ≥ 1.4 mL, sperm concentration ≥ 6 million/mL, progressive motility (PR) ≥ 20% after 3-5 days of abstinence. * Female partners with ≥ 5 mature (MII) oocytes retrieved. * Couples undergoing ICSI with PGT-A and elective single embryo transfer (eSET). * Willingness to participate and sign informed consent.

Exclusion criteria

* Azoospermia, surgical sperm retrieval, or use of cryopreserved sperm. * Female uterine or ovarian conditions severely affecting IVF outcomes. * Use of donor sperm or donor oocytes

Design outcomes

Primary

MeasureTime frameDescription
Clinical Pregnancy Rate after single embryo transfer4 to 6 weeks after embryo transferConfirmed by the presence of an intrauterine gestational sac on ultrasound.

Secondary

MeasureTime frameDescription
Post-processing sperm DNA fragmentation index (DFI, %)Immediately after sperm preparation on the day of oocyte retrievalEvaluated using the LensHooke® R11 Plus assay
Blastocyst rate and good-quality blastocysts rateDay 5 to Day 6 after ICSIEvaluated according to Gardner's criteria and classified following Munné et al. (2019)
Euploidy rate.Within 2 weeks after blastocyst biopsyAssessed via preimplantation genetic testing for aneuploidy (PGT-A) using next-generation sequencing (NGS).

Countries

Vietnam

Contacts

CONTACTSon The Trinh
trinhtheson@vmmu.edu.vn+ 84 902150873

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026